NASDAQ:VANI Vivani Medical Q3 2023 Earnings Report $1.27 -0.01 (-0.78%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Vivani Medical EPS ResultsActual EPS-$0.13Consensus EPS -$0.13Beat/MissMet ExpectationsOne Year Ago EPSN/AVivani Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVivani Medical Announcement DetailsQuarterQ3 2023Date11/14/2023TimeBefore Market OpensConference Call DateTuesday, November 14, 2023Conference Call Time6:00AM ETUpcoming EarningsVivani Medical's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vivani Medical Earnings HeadlinesShort Interest in Vivani Medical, Inc. (NASDAQ:VANI) Declines By 32.5%September 9 at 2:50 AM | americanbankingnews.comSeptember 2025's Promising Penny Stock OpportunitiesSeptember 6 at 1:26 PM | finance.yahoo.comMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.September 9 at 2:00 AM | American Alternative (Ad)Vivani Medical provides update on plans for NPM-139 semaglutide implantSeptember 4, 2025 | msn.comVivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight ManagementSeptember 4, 2025 | globenewswire.comA brewing GLP-1 showdown, from Big Pharma pills to a biotech implantAugust 27, 2025 | finance.yahoo.comSee More Vivani Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email. Email Address About Vivani MedicalVivani Medical (NASDAQ:VANI) Solutions, Inc. (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories. The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity. These products aim to reduce complications associated with percutaneous biopsies while facilitating efficient sample collection and handling, helping clinicians deliver faster and more accurate diagnoses. Vivani Medical serves a broad customer base that encompasses hospitals, outpatient imaging centers and pathology service providers across the United States. In addition to its direct‐sales model, the company has established distribution partnerships to extend its reach into select European and Latin American markets, supporting growing international adoption of its technologies. Founded in 2016 and headquartered in the United States, Vivani Medical became a publicly traded company in mid-2021, listing its common stock on the Nasdaq Capital Market under the ticker symbol “VANI.” The company’s leadership team brings together experienced professionals in medical device innovation, regulatory affairs and commercial operations, driving ongoing efforts to expand its product pipeline and reinforce its position in the interventional radiology market.Written by Jeffrey Neal JohnsonView Vivani Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
